A critical component of the 2026 market is the stabilization of the isotope supply chain through the Jules Horowitz Reactor (JHR). As older European reactors reach their end-of-life, France's JHR has become a cornerstone of global radiopharmaceutical production. In 2026, the facility is operating at peak capacity to produce Technetium-99m (Tc-99m), which still accounts for approximately 80% of all diagnostic nuclear medicine procedures in France.

To complement this reactor-based production, the French government has incentivized the development of Automated Radiosynthesis Modules. These automated facilities are being installed in major hospital hubs to enhance production efficiency and minimize personnel exposure to radiation. This dual-source strategy—combining large-scale reactor output with localized automated synthesis—has shielded the French market from the global isotope shortages that plagued the industry earlier in the decade.

FAQ:

• Question: What is the most used radioisotope in France?

• Answer: Technetium-99m remains the most used, primarily for bone, heart, and lung diagnostics.